INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

NCT03424122 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Lymphoma

Interventions

DRUG: Parsaclisib
DRUG: Rituximab
DRUG: Bendamustine
DRUG: Ibrutinib

Sponsor

Incyte Corporation